LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

38.73 -0.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

38.67

Max

39.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	12.278 80.03
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+18.19% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	554M 2.2B
Ankstesnė atidarymo kaina	39.22
Ankstesnė uždarymo kaina	38.73

Naujienos nuotaikos

By Acuity

50%

182 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-09 22:13; UTC

Uždarbis

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025-12-09 21:40; UTC

Uždarbis

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025-12-09 18:51; UTC

Įsigijimai, susijungimai, perėmimai

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025-12-09 16:57; UTC

Pagrindinės rinkos jėgos

Clear Secure Rises on Medicare Identity Verification Contract

2025-12-09 23:46; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025-12-09 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings Stake in Lenovo Now at 32.34%

2025-12-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025-12-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025-12-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025-12-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025-12-09 23:35; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-12-09 22:42; UTC

Uždarbis

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025-12-09 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-12-09 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-09 21:48; UTC

Rinkos pokalbiai

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025-12-09 20:28; UTC

Rinkos pokalbiai

Oil Futures Decline for Second Straight Session -- Market Talk

2025-12-09 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025-12-09 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Teck Reports Voting Results From Special Meeting of Hldrs

2025-12-09 20:26; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025-12-09 20:21; UTC

Rinkos pokalbiai

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025-12-09 19:52; UTC

Uždarbis

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025-12-09 19:17; UTC

Uždarbis

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025-12-09 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-09 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-09 17:11; UTC

Uždarbis

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

18.19% į viršų

12 mėnesių prognozė

Vidutinis 46 USD 18.19%

Aukščiausias 62 USD

Žemiausias 32 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

182 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.